Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant▼

Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure. Susvimo continuously delivers a customised formulation of ranibizumab over time. Ranibizumab is a vascular endothelial growth factor (VEGF) inhibitor designed to bind to and inhibit vascular endothelial growth factor-A (VEGF-A), a protein that has been shown to play a critical role in the formation of new blood vessels and the leakiness of the vessels.

In the United States, Susvimo is approved for the treatment of people with the vision-threatening retinal condition neovascular or “wet” age-related macular degeneration who have previously responded to at least two anti-VEGF injections.